Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
ORIGINAL ARTICLE
Ahead of print publication  

Lymph node ratio as an independent prognostic factor for breast cancer-related mortality in patients with node-positive breast cancer


1 Department of Radiation Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
2 Anadolu Medical Center, Gebze, Kocaeli, Turkey
3 Department of Radiation Oncology, Acibadem University, Istanbul, Turkey

Date of Submission25-Nov-2019
Date of Acceptance12-Apr-2020
Date of Web Publication19-Oct-2020

Correspondence Address:
Ilknur Alsan Cetin,
Department of Radiation Oncology, Faculty of Medicine, Marmara University, Fevzi Cakmak Mah., Muhsin Yazicioglu Cd. No: 10, 34899 Pendik, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_1034_19

 > Abstract 


Aim: This study assessed whether prognostic information could be obtained in patients with lymph node (LN)-positive breast cancer based on their LN ratios (LNRs) and explored the relationships between other potential prognostic factors and survival.
Setting and Design: This was a retrospective clinical study.
Materials and Methods: This study included 608 women with node-positive nonmetastatic breast cancer. Clinical and pathologic data were retrospectively evaluated. The median age was 51 years (range: 23–84 years). All patients received adjuvant radiotherapy after radical surgery. A total dose of 50 Gy was administered to the chest wall or breast and LN regions with 2 Gy daily fractions. A 10-Gy boost was administered to the breast tumor bed. The cutoff value of LNR was defined as low risk (<0.21) in 278 patients, intermediate risk (0.21–0.65) in 217 patients, and high risk (>0.65) in 113 patients. Prognostic variables included patient characteristics, disease characteristics, and interventional factors. The primary endpoint was overall survival and the secondary endpoint was breast cancer-related mortality.
Statistical Analysis Used: Statistical analyses were performed using the Kaplan–Meier method, log-rank test, and Cox regression analysis. P value was required to be <0.05.
Results: Within a median follow-up period of 95.4 months (range: 5–232.4 months), overall survival rates for 10 and 15 years were 66% and 53%, respectively. Multivariate analysis revealed that LNR (P = 0.026), estrogen receptor status (ERS) (P = 0.021), age (P = 0.04), and smoking (P = 0.024) were independent significant prognostic factors for overall survival. Breast cancer-related mortality rates at 10 and 15 years were 70.7% and 60%, respectively. LNR (P = 0.03) and ERS (P = 0.002) were independent significant prognostic factors for breast cancer-related mortality.
Conclusions: LNR and ERS were significant prognostic factors for survival at all endpoints.

Keywords: Breast cancer, prognostic factors, the lymph node ratio



How to cite this URL:
Cetin IA, Akay SU, Caglar Ozkok HB, Sengoz M. Lymph node ratio as an independent prognostic factor for breast cancer-related mortality in patients with node-positive breast cancer. J Can Res Ther [Epub ahead of print] [cited 2020 Dec 3]. Available from: https://www.cancerjournal.net/preprintarticle.asp?id=298614




 > Introduction Top


For women, the most frequent cancer type is breast cancer and it is the primary cause of cancer-related death. Multiple randomized controlled trials and a meta-analysis have reported that adequate postoperative locoregional radiotherapy for node-positive breast cancer reduces locoregional recurrence and improves the survival rate.[1],[2] The 20-year results of the British Columbia trial also had matching results, indicating significant survival rates when radiotherapy was applied to patients with both 1–3 and 4 or more lymph node (LN) metastases.[3] In addition, a recent meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group showed that adjuvant radiotherapy after mastectomy reduced the 5-year local risk from 16% to 4% in patients with 1–3 LN metastases.[1]

LN assessment is an important disease severity and prognosis indicator in patients with breast cancer.[4],[5] It is commonly achieved through axillary LN dissection. The number of involved axillary nodes has been taken into account for routine clinical decision-making.[6],[7] LNs are classified in accordance with the American Joint Committee on Cancer LN-positive stratification (pNs) in breast cancer. The system is based on the number of positive LNs, where pN0 = no positive nodes, pN1 = 1–3 positive nodes, pN2 = 4–9 positive nodes, and pN3 = 10 or more positive nodes.[8] In several studies, the LN ratio (LNR) compared with the pNs approach is suggested to be more important for the prediction of prognosis in patients with breast cancer.[9],[10],[11],[12],[13],[14],[15],[16],[17],[18] The LNR was recently identified as a strong predictor of breast cancer survival.[12],[17],[18],[19],[20],[21],[22],[23] The LNR is calculated by dividing the number of positive LNs by the total number of excised LNs ([LN+ ]/[total LN retrieved]). Vinh-Hung et al.[16] categorized the LNR as follows: low-risk, <0.2; intermediate risk, 0.2-0.65; and high-risk, >0.65. However, other authors have reported no differences in prognostic value between the LNR and pNs approaches.[12],[14],[17],[22] Hence, the primary goal of this investigation was to determine if the LNR has the same prognostic ability as the pNs approach. In addition, we explored the long-term survival of patients receiving radiotherapy and associated prognostic factors.


 > Materials and Methods Top


In our institutional database, between 1997 and 2010, we identified 608 women with positive LNs who underwent mastectomy or breast-conserving surgery, without any detectable distant metastasis. Prognostic variables included patient characteristics (i.e., age, comorbidity, use of oral contraceptive pills, family history regarding breast cancer, smoking, pregnancy, and menopausal status), disease characteristics (i.e., tumor type, tumor laterality, location, size, grade of cell differentiation, extracapsular involvement, lymphovascular involvement, perioral involvement, number of removed LNs and positive nodes, LNR, and hormone receptor status), and interventional factors (i.e., type of surgery, safe surgical margin, chemotherapy, and hormone therapy). Patient clinicopathological characteristics are shown in [Table 1]. All patients underwent postoperative radiotherapy. A total dose of 50 Gy was administered in 25 fractions. Patients who took breast-conserving surgery or had undergone mastectomy were treated in the supraclavicular region, including the axillary apex and breast wall or breast. A total of 10 Gy radiotherapy was applied to the tumor bed with electron or photon doses during breast radiotherapy. Patients with positive hormone receptor disease received at least 5 years of adjuvant hormone therapy. Overall, 80% of the patients received hormone therapy, 46% of of the patients received tamoxifen, 31% received aromatase inhibitors, and 23% received both. In addition, 41.5% of the patients received taxane-based therapy; 40% received cyclophosphamide, epirubicin, and 5-fluorouracil therapy; and 18.5% received other chemotherapies.
Table 1: Clinicopathological characteristics of patients with breast cancer (n=608)

Click here to view


The LNR was calculated as the total number of positive LNs divided by the total number of LNs obtained. The results were gathered as three groups based on established LNR cutoffs; for this study, LNR cutoffs were defined as low risk (<0.21), intermediate risk (0.21–0.65), and high risk (>0.65). The primary endpoint was overall survival and the secondary endpoint was breast cancer-related mortality. Follow-up time is the time interval between the last radiotherapy and the last follow-up or death. Overall survival is the time between the histologic diagnosis and the last contact or death. The Kaplan–Meier method was used to estimate the survival curves. The two-sided log-rank test was used to test the differences in observed survival distribution among patient subgroups. Univariate and multivariate Cox models were used to evaluate predictive factors. Hazard ratios were reported with 95% confidence intervals (CIs). All P values were two-sided and P < 0.05 was considered to indicate a significant difference. SPSS Statistics for Windows Version 20 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis.


 > Results Top


Over a 21-year period, 608 patients were diagnosed with breast cancer. The mean age at diagnosis was 51 years (range: 23–84 years). The clinicopathological characteristics of patients with node-positive breast cancer are shown in [Table 1]. A large majority of patients (88%) had 10 or more axillary LNs removed. The median number of involved LNs was 15 (range: 1–51 nodes), while the median LNR was 0.24 (range: 0.03–1.00).

The median follow-up was 7.95 years (range: 0.5–19.3 years). Overall survival rates at 5, 10, and 15 years were 80%, 66%, and 53%, respectively (95% CI: 181.1–210.6). In univariate analysis, age (<45 age, 45–65 age, and >65 age; P < 0.0001), oral contraceptive pills (P = 0.001), smoking (P = 0.01), menopausal status (P = 0.008), type of surgery (P = 0.002), tumor size (P = 0.005), number of removed LNs (1–3 LN, 4–6 LN, 6–9 LN, or ≥ 10 LN; P = 0.017), number of positive nodes (1–3 LN+, 4–9 LN+, or ≥ 10 LN+; P < 0.0001), LNR (<0.2, 0.2–0.65, >0.65; P < 0.0001), lymphovascular involvement (P = 0.007), estrogen receptor status (ERS) (P < 0.0001), progesterone receptor status (P < 0.0001), hormone therapy (P < 0.0001), and chemotherapy (P < 0.0001) were significant predictors for overall survival [Table 1]. In multivariate analysis, LNR (<0.2, 0.2-0.65, >0.65; P = 0.007), ERS (P = 0.028), age (<45 years, 45–65 years, >65 years; P = 0.02), and smoking (P = 0.03) were independent significant prognostic factors for overall survival [Table 2]. LNR was an important prognostic factor, with a 1.99-fold increased relative risk. The 10-year overall survival rates for patients with low-risk, intermediate-risk, and high-risk LNRs were 78%, 63.9%, and 37%, respectively (standard error of the mean, 7.5; 95% CI: 181–210; log-rank χ2 =59.1).
Table 2: Multivariate analysis results for overall survival

Click here to view


Breast cancer-related mortality occurred in 164 (28%) patients. Breast cancer-related mortality rates at 5, 10, and 15 years were 83%, 70.7%, and 60%, respectively (95% CI: 205.1–228.3). Oral contraceptive pills (P = 0.003), pregnancy (P = 0.039), marriage (P = 0.001), tumor size (P = 0.014), type of surgery (P = 0.011), number of positive nodes (P < 0.0001), LNR (P < 0.0001), lymphovascular involvement (P = 0.016), ERS (P < 0.0001), progesterone receptor status (P < 0.0001), hormone therapy (P < 0.0001), and chemotherapy (P < 0.0001) were significant predictors for breast cancer-specific survival. LNR (<0.2, 0.2–0.65, >0.65; P = 0.008) and ERS (P = 0.004) were independent significant prognostic factors for breast cancer-related mortality [Table 3]. LNR was the most important prognostic factor, with a 1.87-fold increased relative risk. The 10-year breast cancer-specific survival rates for patients with low-risk, intermediate-risk, and high-risk LNRs were 82%, 69%, and 41.5%, respectively (standard error of the mean: 5.9; 95% CI: 205–228; log-rank χ2 =55.6) [Figure 1].
Table 3: Multivariate analysis results for breast cancer specific survival

Click here to view
Figure 1: Overall and breast cancer-specific survival according to pN and according to lymph node ratio in breast cancer with positive lymph nodes

Click here to view


Metastasis was detected in 164 (27%) patients; 83 (13.6%) patients had multiple metastases. In total, 13% of the patients did not experience an acute side effect during radiotherapy; Grades I, II, and III radiodermatitises were observed in 53%, 33.2%, and 0.7% of the patients, respectively. No lymphedema was observed in 85% of the patients; Grades I, II, and III lymphedemas were observed in 8%, 6.2%, and 0.8% of the patients, respectively.


 > Discussion Top


In this study, we showed that the LNR and ERS are important prognostic factors for breast cancer-related mortality. In addition, LNR, ERS, age, and smoking were independent significant prognostic factors for overall survival. The relative risk values of both LNR and ERS were higher than those of other factors.

The role of positive LNs in predicting breast cancer-related mortality and survival was recently demonstrated in several institutional series.[19],[23],[24],[25],[26] Although these studies differed in many factors (i.e., patient selection, follow-up, surgery type, and adjuvant therapies), they suggested that the percentage of positive LNs is an independent and significant survival prognostic indicator for women having LN-positive breast carcinoma. In these studies, some of the patients received radiotherapy after breast-conserving surgery while some of them didn't receive radiotherapy.[19],[23],[25],[27] In our study, all breast cancers with positive LNs were treated with locoregional radiotherapy.

Voordeckers et al. analyzed the overall survival and cause-specific survival rates as a function of the percent positive LNs in 741 patients with node-positive disease treated with breast-conserving therapy or mastectomy, 97% of whom received radiotherapy.[23] In their multivariate analysis, the percentage of positive LNs was the most significant factor associated with survival. Similar to our results, the total number of positive LNs was not statistically significant when considering the LNR. Truong et al. reported the prognostic significance of the percentage of positive axillary LNs in 542 T1–2 breast cancers with 1–3 positive LNs.[28] These findings are consistent with those of a smaller series from Megale Costa et al. involving 168 patients who had a mean follow-up of only 26 months.[24]

The LNR provided a better patient prognostic risk profile than the pNs approach. When exploring the prognostic value of LNR in our series, we used the same cutoff points identified by Vinh-Hung et al.[16] According to our retrospective multivariate analysis, LNR was statistically significant compared to pathological LNs.

Some studies have shown that percent positive axillary LN involvement predicts survival in patients with nonmetastatic postmastectomy breast cancer who are receiving regional radiotherapy.[18],[29] However, the LNR for radiotherapy treatment of 1–3 LNs may be more useful for clinical decision-making. Therefore, recent studies have focused on the LNR in patients with pN1 breast cancer.[23],[24]

In the population-based cohort study of Liu et al., LNR has been shown to be a prognostic factor, and grade-LNR staging system has been emphasized as a reliable classification.[30] Sweety et al. showed that LNR had a stronger relation with tumor grade than tumor stage.[31] If the number of removed LNs is low in breast cancer patients, there is a negative correlation between the number of removed LNs and OS (usually <10).[32] In the study of Jin et al., it was emphasized that LNR may be a strong LN staging system, especially when used in a limited number of LN dissections.[33] In the study of Wen et al., LNR is an important prognostic parameter and can predict survival more accurately than pN staging and provide an individual prediction. In addition, it is emphasized that it may help clinicians to determine treatment options and prognosis evaluation.[34]


 > Conclusions Top


In this retrospective study, two independent prognostic factors for breast cancer-related mortality were determined: the LNR was the most important, followed by the ERS.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 > References Top

1.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-106.  Back to cited text no. 1
    
2.
Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.  Back to cited text no. 2
    
3.
Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116-26.  Back to cited text no. 3
    
4.
Mazouni C, Rimareix F, Mathieu MC, Uzan C, Bourgier C, André F, et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg 2013;205:662-7.  Back to cited text no. 4
    
5.
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.  Back to cited text no. 5
    
6.
Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 1997;15:2312-21.  Back to cited text no. 6
    
7.
Fountzilas G, Nicolaides C, Aravantinos G, Skarlos D, Kosmidis P, Papakostas P, et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and &amp;gt;/=10 positive axillary lymph nodes. A feasibility study. Oncology 1998;55:508-12.  Back to cited text no. 7
    
8.
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.  Back to cited text no. 8
    
9.
Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr., Improved staging in node-positive breast cancer patients using lymph node ratio: Results in 1,788 patients with long-term follow-up. J Am Coll Surg 2010;210:797-805.e1, 805-7.  Back to cited text no. 9
    
10.
Hatoum HA, Jamali FR, El-Saghir NS, Musallam KM, Seoud M, Dimassi H, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Indian J Surg Oncol 2010;1:305-12.  Back to cited text no. 10
    
11.
Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol 2011;18:3143-8.  Back to cited text no. 11
    
12.
Li Y, Holmes E, Shah K, Albuquerque K, Szpaderska A, Erşahin C. The prognostic value of lymph node cross-sectional cancer area in node-positive breast cancer: A comparison with N stage and lymph node ratio. Patholog Res Int 2012;2012:161964.  Back to cited text no. 12
    
13.
Bai LS, Chen C, Gong YP, Wei W, Tu Y, Yao F, et al. Lymph node ratio is more predictive than traditional lymph node stratification in lymph node positive invasive breast cancer. Asian Pac J Cancer Prev 2013;14:753-7.  Back to cited text no. 13
    
14.
Saxena N, Hartman M, Yip CH, Bhoo-Pathy N, Khin LW, Taib NA, et al. Does the axillary lymph node ratio have any added prognostic value over pN staging for South East Asian breast cancer patients? PLoS One 2012;7:e45809.  Back to cited text no. 14
    
15.
Ahn SH, Kim HJ, Lee JW, Gong GY, Noh DY, Yang JH, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: A report from the Korean breast cancer society. Breast Cancer Res Treat 2011;130:507-15.  Back to cited text no. 15
    
16.
Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 2009;27:1062-8.  Back to cited text no. 16
    
17.
Wu SG, He ZY, Li Q, Sun JY, Li FY, Lin Q, et al. Prognostic value of metastatic axillary lymph node ratio for Chinese breast cancer patients. PLoS One 2013;8:e61410.  Back to cited text no. 17
    
18.
Lale Atahan I, Yildiz F, Ozyigit G, Sari S, Gurkaynak M, Selek U, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol 2008;47:232-8.  Back to cited text no. 18
    
19.
Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, Vlastos G, et al. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008;44:1670-7.  Back to cited text no. 19
    
20.
Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, et al. Prognostic value of nodal ratios in node-positive breast cancer: A compiled update. Future Oncol 2009;5:1585-603.  Back to cited text no. 20
    
21.
Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. The prognostic value of lymph node ratio in node-positive breast cancer: A Dutch nationwide population-based study. Ann Surg Oncol 2013;20:2607-14.  Back to cited text no. 21
    
22.
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol 2012;19:1808-17.  Back to cited text no. 22
    
23.
Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004;70:225-30.  Back to cited text no. 23
    
24.
Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304-6.  Back to cited text no. 24
    
25.
van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481-9.  Back to cited text no. 25
    
26.
Tai P, Yu E, Sadikov E, Mahmood S, Joseph K. Prognostic value of nodal ratios (NR) in node positive breast cancer patients. Int J Radiat Oncol Biol Phys 2006;66(3);Suppl;S7.  Back to cited text no. 26
    
27.
Truong PT, Woodward WA, Thames HD, Ragaz J, Olivotto IA, Buchholz TA. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: An analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007;68:59-65.  Back to cited text no. 27
    
28.
Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006-14.  Back to cited text no. 28
    
29.
Fortin A, Dagnault A, Blondeau L, Vu TT, Larochelle M. The impact of the number of excised axillary nodes and of the percentage of involved nodes on regional nodal failure in patients treated by breast-conserving surgery with or without regional irradiation. Int J Radiat Oncol Biol Phys 2006;65:33-9.  Back to cited text no. 29
    
30.
Liu C, Li H, Zhuo R, Wang L, He L, Ruan Q, et al. Grade-lymph node ratio predicts the survival of breast cancer in different molecular types: A surveillance, epidemiology, and end results population-based analysis. Medicine (Baltimore) 2019;98:e16436.  Back to cited text no. 30
    
31.
Sweety SV, Narayankar AS. Evaluation of lymph node ratio and morphologic patterns of nodal reactive hyperplasia in primary organ malignancy. Indian J Pathol Microbiol 2019;62:216-21.  Back to cited text no. 31
  [Full text]  
32.
Erbes T, Orlowska-Volk M, Zur Hausen A, Rücker G, Mayer S, Voigt M, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer 2014;14:4.  Back to cited text no. 32
    
33.
Jin ML, Gong Y, Pei YC, Ji P, Hu X, Shao ZM. Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems. Breast 2020;49:93-100.  Back to cited text no. 33
    
34.
Wen J, Yang Y, Liu P, Ye F, Tang H, Huang X, et al. Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast 2017;33:14-22.  Back to cited text no. 34
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Cetin IA
    -  Akay SU
    -  Caglar Ozkok HB
    -  Sengoz M
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract>Introduction>Materials and Me...>Results>Discussion>Conclusions>Article Figures>Article Tables
  In this article
>References

 Article Access Statistics
    Viewed120    
    PDF Downloaded9    

Recommend this journal